Uncovering the Pathology of a Rare Pediatric Leukemia
Credit: Northwestern Medicine
A team of scientists has demonstrated the mechanism by which ETO2-GLIS2, a gene fusion, promotes the development of an aggressive form of pediatric leukemia. The findings, published in Cancer Cell, also reveal an opportunity for the development of therapeutics.
The study was co-authored by John Crispino, PhD, the Robert I. Lurie, MD, and Lora S. Lurie Professor of Medicine in the Division of Hematology and Oncology.
Acute megakaryoblastic leukemia (AMKL), a rare type of blood cancer predominantly found in children, has two major pediatric subgroups: AMKL in patients with Down syndrome and those without. While the disease in those with Down syndrome (DS) is relatively well-defined and carries a good prognosis, non-DS AMKL is much less well-understood.
Recently, scientists discovered that a gene fusion called ETO2-GLIS2 — produced by an inversion on chromosome 16 — is present in 20 to 30 percent of cases of non-DS AMKL, and is associated with a very poor patient prognosis. But up until now, it was unclear exactly how this gene fusion blocks normal cell differentiation, a hallmark of leukemia.
In the current study, the scientists illustrated how ETO2-GLIS2 induces an irregular transcription network that underlies AMKL. They further demonstrated that expression of a peptide that inhibits ETO2-GLIS2 oligomerization could release the differentiation block — insights which could inform the development of novel therapeutics.
“Acute megakaryoblastic leukemia is a devastating blood cancer that requires new targeted and efficacious therapies,” Crispino said. “The discovery of the mechanism by which ETO2-GLIS2 fusion promotes leukemia provides important new insights into ways to target these malignant cells.”
This article has been republished from materials provided by Northwestern Medicine. Note: material may have been edited for length and content. For further information, please contact the cited source.
Thirant, C., Ignacimouttou, C., Lopez, C. K., Diop, M., Mouël, L. L., Thiollier, C., . . . Mercher, T. (2017). ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 31(3), 452-465. doi:10.1016/j.ccell.2017.02.006
Availability of Brain Tumor Surgery Dye Increases for NHS PatientsNews
A chemical dye that lights up brain tumours during surgery should be available to more NHS patients in England, according to the National Institute for Health and Care and Excellence (NICE).READ MORE
How Well Do Cancer Drugs Hit Their Targets? Here’s How to Find OutNews
Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach.READ MORE